These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3583646)

  • 1. Clinical pharmacology of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
    Green RM; Stewart DJ; Maroun JA
    Invest New Drugs; 1986; 4(4):387-94. PubMed ID: 3583646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
    Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM
    Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion.
    Trump DL; Tutsch KD; Koeller JM; Tormey DC
    Cancer Res; 1985 Jun; 45(6):2853-8. PubMed ID: 3986812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys.
    Grygiel JJ; Balis FM; Collins JM; Lester CM; Poplack DG
    Cancer Res; 1985 May; 45(5):2037-9. PubMed ID: 3986760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of tiazofurin by human erythrocytes and mononuclear blood cells in vitro.
    Roberts JD; Tong WP; Hartshorn JN; Hacker MP
    Cancer Lett; 1986 Aug; 32(2):193-7. PubMed ID: 3756845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of tiazofurin in dogs.
    Obeng EK; Vallner JJ; Cadwallader DE; Tackett RL
    Biopharm Drug Dispos; 1987; 8(2):125-32. PubMed ID: 3593893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193).
    Balis FM; Lange BJ; Packer RJ; Holcenberg JS; Ettinger LJ; Sallan SE; Heideman RL; Zimm S; Smithson WA; Cogliano-Shutta NA
    Cancer Res; 1985 Oct; 45(10):5169-72. PubMed ID: 4027992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective sensitivity to tiazofurin of human leukemic cells.
    Jayaram HN; Pillwein K; Nichols CR; Hoffman R; Weber G
    Biochem Pharmacol; 1986 Jun; 35(12):2029-32. PubMed ID: 3718544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286193) administered by continuous infusion.
    Batist G; Klecker RW; Jayaram HN; Jenkins JF; Grygiel J; Ihde DC; Eddy JL; Fine RL; Kerr IG; Collins JM
    Invest New Drugs; 1985; 3(4):349-55. PubMed ID: 4086242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The disposition and metabolism of tiazofurin in rodents, rabbits, and dogs.
    Arnold ST; Jayaram HN; Harper GR; Litterst CL; Malspeis L; DeSouza JJ; Staubus AE; Ahluwalia GS; Wilson YA; Cooney DA
    Drug Metab Dispos; 1984; 12(2):165-73. PubMed ID: 6144481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion.
    Raghavan D; Bishop J; Sampson D; Grygiel J; Woods R; Coates A; Fox R
    Cancer Chemother Pharmacol; 1986; 16(2):160-4. PubMed ID: 3948303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation.
    Roberts JD; Stewart JA; McCormack JJ; Krakoff IR; Culham CA; Hartshorn JN; Newman RA; Haugh LD; Young JA
    Cancer Treat Rep; 1987 Feb; 71(2):141-9. PubMed ID: 3802111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
    Maroun JA; Stewart DJ
    Invest New Drugs; 1990; 8 Suppl 1():S33-9. PubMed ID: 2380015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion.
    Jayaram HN; Lapis E; Tricot G; Kneebone P; Paulik E; Zhen W; Engeler GP; Hoffman R; Weber G
    Int J Cancer; 1992 May; 51(2):182-8. PubMed ID: 1568787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin.
    Ahluwalia GS; Jayaram HN; Plowman JP; Cooney DA; Johns DG
    Biochem Pharmacol; 1984 Apr; 33(8):1195-203. PubMed ID: 6143562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of resistance to tiazofurin in hepatoma 3924A.
    Jayaram HN; Pillwein K; Lui MS; Faderan MA; Weber G
    Biochem Pharmacol; 1986 Feb; 35(4):587-93. PubMed ID: 2868729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unique bioactivation of tiazofurin--studies with resistant cells.
    Kuttan R
    Indian J Biochem Biophys; 1989 Jun; 26(3):160-5. PubMed ID: 2620910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of tiazofurin in plasma by high-performance liquid chromatography.
    Klecker RW; Collins JM
    J Chromatogr; 1984 May; 307(2):361-9. PubMed ID: 6736183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4-carboxamide adenine dinucleotide (TAD).
    Ahluwalia GS; Cooney DA; Marquez VE; Jayaram HN; Johns DG
    Biochem Pharmacol; 1986 Nov; 35(21):3783-90. PubMed ID: 2877671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial and biochemical evaluation of tiazofurin administered on a weekly schedule.
    Melink TJ; Sarosy G; Hanauske AR; Phillips JL; Bayne JH; Grever MR; Jayaram HN; Von Hoff DD
    Sel Cancer Ther; 1990; 6(1):51-61. PubMed ID: 2343202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.